daniel drucker glp 1 2026 Baxter Foundation Distinguished Lecture/ReMS - Drucker, MD, Senior Scientist, Lunenfeld-Tanenbaum Research Institute "GLP-1 medicines, how and where do they work?" Rolling out the red carpet

Doctors are expecting an onslaught of new patients: As Axios reported in June, clinics are worried they may be overwhelmed by the increased demand that follows the Bridge programs launch

Constipation is often most pronounced during dose escalation phases and may improve with continued therapy as the body adapts

Third-Party Test Results (Certificate of Analysis)

your clinician will discuss potential benefits, risks, and alternatives

For the broader GLP-1 market, Canadas first generic semaglutide approval shows how the access debate is shifting from shortage-era workarounds to formal generic competition, with each countrys patent rules determining the pace

But oral rivaroxaban or apixaban could be an option instead of heparin if your pulmonary embolism is small